Loading stock data…
ASRT
$18.47+0.04 (+0.22%)
Market ClosedLast close May 1
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Assertio Holdings, Inc. in the Healthcare sector is trading at $18.47. The stock is currently near its 52-week high of $20.45, remaining 45.8% above its 200-day moving average. Technical signals show overbought RSI of 81 and bearish MACD signal, explaining why ASRT maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 81) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.47
Potential Upside
5%
Whystock Fair Value$19.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$116.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.33%
Volume
Today's trading volume
133,973
Recent News
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Here is how Assertio (ASRT) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
How The Assertio Holdings (ASRT) Story Is Shifting With The Takeover And Reset Valuation
Assertio Holdings is back in focus after its fair value estimate was reset from US$37.44 to US$21.33, a cut of roughly 43% that reflects a more cautious stance on the stock. Analysts are weighing this price target change against the takeover agreement, with some seeing reduced standalone uncertainty, while others highlight capped upside and integration risk. Read on to see how to interpret these shifts and keep up with the evolving narrative around Assertio. Analyst Price Targets don't always...
Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 115.1% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
Assertio Holdings (ASRT) Issues 2026 Sales Guidance After Wider 2025 Losses Has The Bull Case Changed?
Earlier in March 2026, Assertio Holdings, Inc. reported fourth-quarter 2025 revenue of US$13.54 million, down from US$32.18 million a year earlier, alongside a wider quarterly net loss of US$11.93 million and a full-year 2025 net loss of US$30.38 million on revenue of US$118.71 million. At the same time, the company issued 2026 guidance for GAAP net product sales of US$110.0 million to US$125.0 million, giving investors a reference point to compare against prior-year performance and...